The IPO calendar features multiple scheduled U.S. listings in October and November 2026, including Iambic Therapeutics and City Therapeutics in mid-month alongside recent pricings such as Retension Pharmaceuticals and TRex Bio. Strong capital formation data for the first half of 2026 shows 208 IPOs raising over $137 billion, with corporate proceeds up sharply year-over-year and SPAC activity also elevated. AI-related names like Anthropic remain prominent in the pipeline, with marketing potentially beginning in early November and trading targeted before year-end. Traders monitor equity market liquidity, Treasury yields, and regulatory timelines as key variables that could influence deal timing or withdrawals before January 1, 2027.